Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 2Other 2Gynecologic 2Genitourinary 2Breast 2Plasma cell 1Other solid neoplasm 1Other neoplasm 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Mesothelioma 1Lung Diseases 1

Interventions

Carboplatin 10Cisplatin 7Pemetrexed 6Vincristine 5Nivolumab 5Etoposide 4Topotecan 3Specimen Handling 3Ipilimumab 3Injections 3Doxorubicin 3Talc 2Radiotherapy 2Paclitaxel 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Filgrastim 2Drug Therapy 2Cyclophosphamide 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1sintilimab 1ranpirnase 1raltitrexed 1pertuzumab 1pembrolizumab 1onartuzumab 1iniparib 1durvalumab 1dostarlimab 1crofelemer 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Surveys and Questionnaires × Other solid neoplasm × Clear all
NCT02511600 2015-12-15

Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication

M.D. Anderson Cancer Center

Phase 3 Withdrawn
Other solid neoplasmThoracic

Lung Diseases, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡